Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Aurinia Pharmaceuticals ( (AUPH) ) is now available.
Aurinia Pharmaceuticals reported significant financial growth for the third quarter of 2025, with LUPKYNIS sales increasing by 27% and total revenue reaching $73.5 million, an 8% rise from the previous year. The company has raised its 2025 sales guidance, reflecting strong momentum from updated lupus nephritis treatment guidelines and positive results from a Phase 1 study of aritinercept, which is advancing towards clinical studies in two autoimmune diseases.
The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals demonstrates strong financial performance and positive earnings call highlights, contributing to a favorable outlook. However, the stock’s high valuation and technical indicators suggest caution. The absence of corporate events further consolidates the focus on financial and earnings performance.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing therapies for autoimmune diseases with significant unmet medical needs. The company introduced LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, and is also developing aritinercept for potential treatment of autoimmune diseases.
Average Trading Volume: 1,769,686
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
See more data about AUPH stock on TipRanks’ Stock Analysis page.
